News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Hampton Malcolm Garret
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/09/2023 |
4
| Hampton Malcolm Garret (Director) has filed a Form 4 on IDEAYA Biosciences, Inc.
Txns:
| Granted 16,200 options to buy
@ $25.4, valued at
$411.5k
|
|
06/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/30/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/30/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
01/13/2020 |
4
| Hampton Malcolm Garret (SVP Clinical Genomics Group) has filed a Form 4 on ILLUMINA, INC.
Txns:
| Paid exercise price by delivering 326 shares
@ $334.6, valued at
$109.1k
|
|
11/07/2019 |
4
| Hampton Malcolm Garret (SVP Clinical Genomics Group) has filed a Form 4 on ILLUMINA, INC.
Txns:
| Paid exercise price by delivering 492 shares
@ $300.87, valued at
$148k
|
|
03/22/2019 |
4
| Hampton Malcolm Garret (SVP Clinical Genomics Group) has filed a Form 4 on ILLUMINA INC
Txns:
| Paid exercise price by delivering 358 shares
@ $242.8, valued at
$86.9k
|
|
01/11/2019 |
4
| Hampton Malcolm Garret (SVP Clinical Genomics Group) has filed a Form 4 on ILLUMINA INC
Txns:
| Paid exercise price by delivering 327 shares
@ $305.24, valued at
$99.8k
|
|
12/13/2018 |
4
| Hampton Malcolm Garret (EVP Clinical Genomics Group) has filed a Form 4 on ILLUMINA INC
Txns:
| Granted 1,901 shares
@ $0 Granted 5,701 options to buy
@ $0 |
|
11/07/2018 |
4
| Hampton Malcolm Garret (EVP Clinical Genomics Group) has filed a Form 4 on ILLUMINA INC
Txns:
| Paid exercise price by delivering 253 shares
@ $324.14, valued at
$82k
|
|
12/13/2017 |
4
| Hampton Malcolm Garret (EVP Clinical Genomics Group) has filed a Form 4 on ILLUMINA INC
Txns:
| Granted 2,920 shares
@ $0 Granted 8,758 options to buy
@ $0 |
|
02/17/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
|
|